Department of Biomedical Sciences
YOO WOOK KWON Professor
Researchers
Total 5
Department of Biomedical Sciences
SeungHwan Lee Professor
Clinical Pharmacology
New Drug Development
Early Phase Clinical Trial
Personalized Optimal Pharmacotherapy
Pharmacogenomics
Department of Biomedical Sciences
Eun Ju Lee Professor
Aging
fibrosis
Neurodegenerative Diseases
Immune-mediated Diseases
Stem Cells
Peptide
Exosomes
Mitochondria biology
Drug Delivery Systems
Advanced Regenerative Medicine
Good Manufacturing Practice (GMP) Quality Assurance
Department of Biomedical Sciences
H D JANG Professor
Department of Biomedical Sciences
Sung Soo Chung Professor
Obesity
Diabetes
Metabolic dysfunction-Associated Steatohepatitis (MASH)
Metabolic diseases
Endocrine diseases
Cell and Molecular Biology
Regulation of Gene Expression
Post-translational Modifications (PTM)
Therapeutic Development for Metabolic Diseases
Faculty Details
Department of Biomedical Sciences
YOO WOOK KWON
Faculty Details
Department of Biomedical Sciences
SeungHwan LeeMD, PhD
Research Field
Clinical Pharmacology
New Drug Development
Early Phase Clinical Trial
Personalized Optimal Pharmacotherapy
Pharmacogenomics
Brief Summary
Dr. SeungHwan Lee is currently a Professor of Department of Clinical Pharmacology and Therapeutics and the Head of Clinical Trial Support Office & Quality Improvement Office of Clinical Trials Center at Seoul National University Hospital (SNUH).
He is interested in various topics related to early phase clinical trials for new drug development, PK-PD modeling & simulation, and individualized pharmacotherapy based on pharmacogenomics.
In recent years, Dr. Lee has been participating in more than twenty clinical research projects annually as either principal investigator or co-investigator. These projects involve drugs (small molecules and biologics) and innovative therapeutics in a wide range of therapeutic areas, spanning over various kinds of study types such as first-in-human (FIH) studies, PK-PD studies, drug-drug interaction (DDI) studies, vaccine studies, clinical pharmacogenomic (PGx) studies, and PK-PD support in phase 2 or 3 trials. With such expertise, he gives consultations regarding clinical drug development to researchers, pharmaceutical companies, and other interested bodies.
In addition, Dr. Lee is leading a global collaborative research project called INID-K (International Network for Infectious Disease Research & Development of Korea). Through this project, he tries to facilitate the global development of vaccines and treatments by educating and training foreign researchers in the field of clinical trials.
leejh413@snu.ac.kr
Online Profiles
Faculty Details
Department of Biomedical Sciences
Eun Ju LeePhD
Research Field
Aging
fibrosis
Neurodegenerative Diseases
Immune-mediated Diseases
Stem Cells
Peptide
Exosomes
Mitochondria biology
Drug Delivery Systems
Advanced Regenerative Medicine
Good Manufacturing Practice (GMP) Quality Assurance
Brief Summary
Research Overview
Research focuses on elucidating the molecular and pathogenic mechanisms underlying intractable diseases, including aging, fibrosis, neurological disorders, and immune-related diseases, with the ultimate goal of developing next-generation therapeutic strategies that target the fundamental causes of disease. Leveraging gene-based approaches, particularly gene therapy, my research integrates advanced therapeutic modalities—including stem cells, peptides, exosomes, and mitochondria—with drug delivery system (DDS) platforms to develop innovative, mechanism-based therapies with enhanced precision and therapeutic efficacy
Research Vision
Research is inherently interdisciplinary, encompassing molecular biology, genetic engineering, biomedical engineering, and regenerative medicine, with a strong emphasis on translational research that bridges fundamental discoveries and clinical application. I pursue the development of advanced biopharmaceuticals—including gene therapies, cell therapies, and exosome-based therapeutics—through a comprehensive R&D framework spanning basic research, preclinical and clinical development, GMP-based manufacturing and quality assurance, and technology commercialization. Ultimately, my goal is to translate scientific discoveries into clinically meaningful therapies that improve patient outcomes while contributing to the advancement of regenerative medicine and the global biopharmaceutical industry.
Education
- 2001~2005 PhD. Seoul National University
Career
- 2007~2012 Assistant Professor, Clinical Research Institute, Seoul National University Hospital
- 2012~2018 Associate Professor, Biomedical Research Institute, Seoul National University Hospital
- 2018~present Professor, Biomedical Research Institute, Seoul National University Hospital
- 2018~present Professor, Seoul National University College of Medicine
leeunju@snu.ac.kr
Etc
7 Technology Licensing
2 Commercialization
Articles (2021~)
-Retinol from hepatic stellate cells via STRA6 induces lipogenesis on hepatocytes during fibrosis. Cell & Bioscience 2021 (Corresponding)
-Discovery of Chemerin as the new chemoattractant of human Mesenchymal Stem Cells. Cell & Bioscience 2021 (Corresponding)
-Endothelin-1 enhances the regenerative capability of human bone marrow-derived mesenchymal stem cells in a sciatic nerve injury mouse model. Biomaterials 2021 (Corresponding)
-Effect of human peripheral blood mononuclear cells (hPBMCs) on mouse endometrial cell proliferation: a potential therapeutics for endometrial regeneration. Gynecologic and Obstetric Investigation 2022 (Corresponding)
-Smart Gene Smart Gene Therapeutics for Selective Targeting of Myofibroblasts Derived from Hepatic Stellate Cells and Limited Expression under Inflamed Conditions. Clinical and Translational Medicine 2022 (Corresponding)
-Discovery of 3,7-dimethoxyflavone that inhibits liver fibrosis based on dual mechanisms of antioxidant and inhibitor of activated hepatic stellate cell. Free Radical Biology and Medicine 2023 (Corresponding)
-A radioactive CRISPR interference system using 89Zr-labeled LbCas12a J Control Release. 2024
-Transcriptional Intermediary Factor 1γ–Induced Irisin in Skeletal Muscle Attenuates Renal Fibrosis in Diabetic Nephropathy. J of Cachexia, Sacopenia and Muscle 2025
-Transcriptional intermediary factor 1 gamma prevents lung inflammation and fibrosis via alveolar type 2 cells, fibroblasts, and macrophages. 2025 (Corresponding)
-One-day rapid sterility test for human-derived biopharmaceuticals. Nature Biomedical Engineering 2025 (Corresponding)
-Transcriptional intermediary factor 1 gamma-based multitarget gene therapeutic strategy for triple-negative breast cancer. STTT 2026 (Corresponding)
Faculty Details
Department of Biomedical Sciences
H D JANG
Faculty Details
Department of Biomedical Sciences
Sung Soo ChungPhD
Research Field
Obesity
Diabetes
Metabolic dysfunction-Associated Steatohepatitis (MASH)
Metabolic diseases
Endocrine diseases
Cell and Molecular Biology
Regulation of Gene Expression
Post-translational Modifications (PTM)
Therapeutic Development for Metabolic Diseases
Brief Summary
Our research investigates the molecular mechanisms by which transcription factors involved in lipid metabolism and adipocyte and pancreatic β-cell differentiation are regulated by specific agonists and intracellular signaling pathways. In particular, we study how transcription factor activity is controlled not only by ligand activation but also by post-translational modifications (PTMs).
Among various PTMs, our laboratory has a particular interest in SUMOylation and its regulatory role in metabolism. We generate tissue-specific knockout mouse models targeting selected deSUMOylating enzymes in metabolically important tissues, including skeletal muscle, adipose tissue, liver, pancreatic islets, and immune cells. Using dietary intervention-induced models of obesity, diabetes, and steatohepatitis, we investigate how SUMOylation influences lipid metabolism, glucose homeostasis, and the pathogenesis of metabolic disorders at both physiological and molecular levels.
In addition to mechanistic studies, we have identified natural compounds that regulate lipid metabolism and are developing structurally optimized derivatives as potential therapeutic agents for obesity, diabetes, and other metabolic diseases.
Education
- 1984~1988 Seoul National University, College of Natural Science, B.S.
- 1988~1990 Seoul National University, College of Natural Science, M.S.
- 1991~1997 University of Iowa, Department of Biochemistry, Ph.D.
Career
- 1998-2001 Seoul National University, School of Biological Sciences, Postdoc Researcher
- 2002~2005 Seoul National University Hospital, Research Professor
- 2007~2012 Seoul National University Hospital, Biomedical Research Institute, Assistant Professor
- 2012~2024 Seoul National University Hospital, Biomedical Research Institute, Associate Professor
- 2024~ Seoul National University Hospital, Department of Biomedical Science, Professor
suschung@snu.ac.kr